Novartis

An innovative medicines company working to reimagine medicine. See our community guidelines:

[Novartis @Novartis]

@jaymzryanza Hi James,
Thank you for your enquiry. We recommend you contact our local office in South Africa by phone at [phone] for this matter. For additional contact information, visit this page: https://t.co/6w2hmGXFCN
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

Dear SREEJESH P.V,
Thank you for your enquiry. We recommend you contact our local office in India for this matter. They can be reached by phone at [phone] or [phone]​. The local team will follow up with you directly once you contact them.
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

#Investors:
Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance.

Press release: https://t.co/knIbxtaBMP
IR Webcast: https://t.co/Lv4xwJj07V

#NVSQ126 $NVS $NOVN

[Novartis @Novartis]

Hi Jill smith,
Thank you for your message. We recommend that you consult your physician about your interest in clinical trials. For general information about Novartis clinical trials you can visit: https://t.co/eu4ssqUC5c or https://t.co/iPTKEI5ksM
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

@RajeshAnish5827 @RajeshAnish5827 We saw your tweet and would like to know more about your circumstances. Please provide your contact info and social media username to [email protected] so we can follow up.

[Novartis @Novartis]

@sharmajika_son Dear Sharma ji ka ladka,
Thank you for your enquiry. We recommend you contact our local office in India by phone at [phone] or [phone]. For additional contact information, visit this page:https://t.co/hOfZtkkiJK
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

#NVSQ126 Novartis social media posts on Q1 2026 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information.

#NVSQ126 Novartis social media posts on Q1 2026 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis.

$NVS $NOVN

[Novartis @Novartis]

On Tuesday, April 28, Novartis will announce its Q1 2026 results. Register to listen here: https://t.co/sqIHE3oefG

#NovartisNews $NVS $NOVN #NVSQ126

[Novartis @Novartis]

@JaniceDean Hi Janice, we’re really sorry to hear what you’re going through. Could you please follow & DM us to share your email or contact information so we can follow up directly?

[Novartis @Novartis]

@minieb1 @minieb1 Thanks for reaching out. We take product safety seriously and would like to know more about your circumstances. Please provide your contact info and social media username to [email protected] so we can follow up.

[Novartis @Novartis]

@SumitUrge @SumitUrge We saw your tweet. We are sorry to hear about your experience. Please provide your contact info and social media username to [email protected] so we can follow up.

[Novartis @Novartis]

Dear @haryowibowo87,
Thank you for your enquiry. For product related information we recommend you contact our local office in Indonesia by phone at [phone]. For additional contact information, visit this page: https://t.co/MBRgTHoYNC. The local team will follow up with you directly once you contact them.
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

@SukhbirRangi Hi @SukhbirRangi,
Thank you for your message. We recommend you contact our local office near you for more information. For information on how to contact Novartis country offices, visit this page: https://t.co/5qSgj6Zi4i
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

@ucpotracasudnus Dear Acar,
Thank you for your message. Kindly note Sandoz is no longer a Novartis division. Please contact Sandoz by following this link: https://t.co/oMfEiZBoOf
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

#NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information.

#NVSQ425 Novartis social media posts on Q4 and Full-Year 2025 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website Novartis quarterly financial results | Novartis.

$NVS $NOVN

[Novartis @Novartis]

@nhoqueiro @nhoqueiro We saw your tweet. We are sorry to hear about your experience. Please provide your contact info and social media username to [email protected] so we can follow up.

[Novartis @Novartis]

Dear Carlos G Yescas Solis,

Thank you for reaching out about your baby - we understand your desire to seek treatment urgently for him. We care about every patient in need of treatment, and we recognize the burden and emotional toll that spinal muscular atrophy (SMA) may have on families.

Due to regulatory restraints, all enquiries regarding access to treatment with Onasemnogene Abeparvovec (Zolgensma) need to be submitted to your local Medical Information team directly at https://t.co/K1evNXW4VF or https://t.co/5S9jZYz89q.

Thank you once again for reaching out to us.

Yours sincerely,
Novartis Community Manager

[Novartis @Novartis]

#Investors: Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Press release: https://t.co/LsQDK889sL
IR Webcast: https://t.co/2ZdKCI1G2z

#NVSQ425

[Novartis @Novartis]

Dear Cristina navarro,
Thank you for your message. We recommend that you consult your physician about your interest in clinical trials. For general information about Novartis clinical trials you can visit: https://t.co/eu4ssqUC5c or https://t.co/iPTKEI5ksM
Kind regards,
Novartis Community Manager

[Novartis @Novartis]

@GMJelly1024 Hi @GMJelly1024,
Thank you for your message. Please let us know which country you are in so we can help connect you to the right resource.
Kind Regards,
Novartis Community Manager

[Novartis @Novartis]

@Yerramsetty666 @NovartisScience @NovartisMedical Thank you for reaching out. While we can’t discuss specific patient circumstances for privacy reasons, we recommend you contact our EMEA Medical Information team at [email protected] to learn about all applicable support & resources available.